Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Regeneron Pharmaceuticals, Inc
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study of REGN1979 (anti-CD20 and anti- CD3) and REGN2810 (anti-PD-1) in Patients with a Specific Type of Blood Cancer Estudio de REGN1979 (anti-CD20 y anti- CD3) y REGN2810 (anti-PD-1) en pacientes con un tipo específico de cáncer en la sangre
The primary objective of the study is to assess safety, tolerability and dose limiting toxicity (DLT) of: · Single-agent REGN2810 in patients with B-cell malignancies including HL · Single-agent ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to determine the appropriate dose(s) of Dupilumab (REGN668) in adult patients with moderate to severe atopic dermatitis (eczema)
The primary objective of the study is to assess the efficacy of multiple REGN668 dose-regimens, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy
The primary objective of this study is to assess the safety and tolerability of 160 mg of subcutaneous (SC) therapy with rilonacept in the prophylaxis of gout flares in subjects on urate lowering ther...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterol
*To determine the efficacy, long-term safety, and tolerability of a dosing regimen of 300 mg alirocumab q4w and its potential as a starting regimen.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study in which patients will be assigned, by chance, to receive either the active drug Praluent or a dummy-drug, (a placebo), without anybody knowing what that are assigned to, to determine if there is any effect on memory and reaction time, (known as Neurocognitive Function), when taking Praluent, in Patients with high cholesterol with high and very high risk for heart and blood vessel diseases
The primary objective of the study is to evaluate neurocognitive function with use of Praluent after 96 weeks of treatment versus placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
Efficacy and Safety of REGN727/SAR236553 added-on to Atorvastatin versus Ezetimibe added-on to Atorvastatin versus Atorvastatin dose increase versus switch to Rosuvastatin in patients who are not controlled on Atorvastatin Eficacia y la seguridad de REGN727 añadido a atorvastatina en comparación con ezetimiba, añadido a atorvastatina en comparación con el aumento de dosis de atorvastatina y añadido a atorvastatina en comparación con el cambio de tratamiento a rosuvastatina en pacientes que no están controlados con atorvastatina
To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN727 as add-on therapy to atorvastatin in comparison with ezetimibe (EZE) as add-on therapy to atorvastatin, in compariso...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to determine the safety and tolerability of REGN668 in patients aged ≥6 to <18 years with atopic dermatitis (eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD)
The primary objective of the study is to demonstrate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe AD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to see if multiple doses of REGN668 given by injections under the skin is safe to use in adult patients with moderate-to-severe atopic dermatitis when given at the same time as topical corticosteroids
The primary objective of the study is to assess the safety of repeated subcutaneous (SC) doses of REGN668 administered concomitantly with topical corticosteroids (TCS) in adult patients with moderate-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
The primary objective of this study is to estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) CSCC (Group 1) or with unresectable locally advanced CSC...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
Suivant